Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance

Abstract excerpt

Activating mutations in the catalytic kinase domain of the epidermal growth factor receptor (EGFR) are crucial drivers of non-small cell lung cancer (NSCLC). Our understanding of the structural changes induced by such mutations has evolved alongside the rational design of targeted tyrosine kinase inhibitors (TKIs), leading to improved anti-tumor responses through appropriate patient stratification. However,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to Lung Cancer Treatments and Mutations
• Share to Quinazolinone synthesis and applications